Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a phase III, randomized, controlled trial (ESTEEM 1) - 16/03/14
Doi : 10.1016/j.jaad.2014.01.722
Le texte complet de cet article est disponible en PDF.
Kristian Reich, MD, SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany; Christopher Griffiths, MD, Dermatology Centre, University of Manchester, Manchester, United Kingdom; Craig Leonardi, MD, Saint Louis University School of Medicine, St. Louis, MO, United States; Kim Papp, MD, Probity Medical Research, Waterloo, Canada; Leon Kircik, MD, Physicians Skin Care, PLLC, Louisville, KY, United States; Robert Day, PhD, Celgene Corporation, Warren, NJ, United States; Sergio Chimenti, MD, University of Rome Tor Vergata, Rome, Italy
Le texte complet de cet article est disponible en PDF.| Sponsored 100% by Celgene Corporation. |
© 2014
Publié par Elsevier Masson SAS.
Vol 70 - N° 5S1
P. AB174 - mai 2014 Retour au numéro
Article précédent
- Lipid and cardiovascular effects of statin therapy in patients with and without psoriasis: A post hoc analysis of 3 large cardiovascular endpoint trials
- Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?